Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Scientists probe strategies to repair neuron damage in multiple sclerosis.
FOCiS 2015 Meeting: Immunology by the Bay
12th International Society of Neuroimmunology Congress
Quantifying the early stages of remyelination following cuprizone-induced demyelination.
Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.
New diagnostic criteria for multiple sclerosis: guidelines for research protocols.
Parenteral Dilantin®
Health-related quality of life in multiple sclerosis: Direct and indirect effects of comorbidity.
FOCIS 2014: Spotlight on Translational Immunology
ACTRIMS-ECTRIMS 2014 -- Day 1, afternoon
Gas6 deficiency increases oligodendrocyte loss and microglial activation in response to cuprizone-induced demyelination.
SMC Says Yes to Aubagio® (teriflunomide), a New Once Daily First-line Oral Treatment Available for People with an Active Relapsing Remitting Form of MS
BIIB033 single ascending dose study in healthy volunteer subjects
Cigarette smoking and autoimmune disease: what can we learn from epidemiology?
Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination.
Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis.
Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).
Episode 38 with Dr. Joseph Berger on progressive multifocal leukoencephalopathy
Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study.
Remyelination in experimental models of toxin-induced demyelination.
Immunopathogenesis of neuromyelitis optica.
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study.
Episode 56 with Dr. Gavin Giovannoni, on early phase 3 results of ocrelizumab, the first experimental drug to show some benefit in a progressive form of multiple sclerosis in a major trial
ECTRIMS 2015
2015 Annual Meeting of the Consortium of the Multiple Sclerosis Centers

Pages